MS
MRNA icon

Maven Securities’s Moderna MRNA Stock Holding History

Maven Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,769
Closed -$596K – 1110
2023
Q3 		$596K Buy
+5,769
New +$644K 0.01% 768
2022
Q4 		– Sell
-12,930
Closed -$2.11M – 1023
2022
Q3 		$1.53M Buy
12,930
+9,247
+251% +$1.4M 0.03% 388
2022
Q2 		$526K Sell
3,683
-2,294
-38% -$328K 0.02% 559
2022
Q1 		$1.03M Buy
5,977
+3,281
+122% +$552K 0.04% 324
2021
Q4 		$685K Buy
2,696
+1,495
+124% +$437K 0.02% 462
2021
Q3 		$465K Sell
1,201
-3,299
-73% -$1.22M 0.02% 675
2021
Q2 		$1.06M Buy
+4,500
New +$804K 0.04% 421
2019
Q4 		– Sell
-10,500
Closed -$165K – 393
2019
Q3 		$165K Buy
+10,500
New +$155K 0.05% 184

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maven Securities's MRNA Position: Q4 2023 in Review

Maven Securities sold out of Moderna (MRNA) in Q4 2023, closing a stake of 5,769 shares — an estimated $596K sold.

Maven Securities first reported a position in MRNA in Q3 2019 and held it in 8 quarters. The position peaked at $1.53M in Q3 2022. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Maven Securities reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 5,769 Moderna shares in Q4 2023, an estimated $596K.
  • Maven Securities first reported a position in Moderna in Q3 2019 and held it in 8 quarters.
  • Maven Securities's Moderna position peaked at $1.53M in Q3 2022.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.